We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Kyverna Therapeutics, a clinical-stage cell therapy company, has entered into a non-exclusive, multi-year licence and supply agreement with Oxford Biomedica, a viral vector contract and development manufacturing organisation
Merck has revealed two strategic collaborations in drug discovery that leverage the capabilities of artificial intelligence (AI) for design and discovery. These partnerships involve BenevolentAI based in London,
The European Commission has approved ViiV Healthcare’s Apretude (cabotegravir long-acting (LA) injectable and tablets) to prevent HIV (human immunodeficiency virus). ViiV Healthcare is the specialist HIV company majority
Traverse Biotech, a US-based biotechnology firm, has entered into a license agreement with Genmab under which Traverse will develop and commercialise a bispecific antibody designed for cancer immunotherapy.
Moderna and Immatics, a clinical-stage biopharmaceutical company specialising in the discovery and development of T cell-redirecting cancer immunotherapies, have announced a strategic research and development collaboration. The partnership
Palantir Technologies and Gemelli Generator Real World Data (RWD), a research facility affiliated with Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), have unveiled a collaborative partnership. The
Verily, a precision health technology company of Alphabet, has announced a multi-year collaboration with Kyverna Therapeutics, a clinical-stage cell therapy company. The primary objectives of the collaboration include
NextGen Healthcare, a provider of cloud-based healthcare technology solutions, has entered into a definitive agreement to be acquired by Thoma Bravo, a software investment firm. Following the successful
Thorne HealthTech has entered into a definitive agreement with L Catterton, a prominent global investment firm, under which L Catterton will initiate a tender offer to acquire all
South Korea-based GC Biopharma has signed a Memorandum of Understanding (MOU) with Eubiologics to establish a collaborative effort for the co-production of Euvichol, an oral cholera vaccine. Under